Leo Pharma boss on newly purchased drug: "It is a very cleverly designed antibody"
Kim Kjøller, research director at Leo Pharma, wants to attack atopic dermatitus from all sides, and the company's new DKK 3.9 billion (USD 569 million) purchase is an addition to that plan.
BY KEVIN GRØNNEMANN, TRANSLATED BY CATHERINE BRETT
On Wednesday, Leo Pharma added another potential weapon to its arsenal of treatments for skin disease atopic dermatitis (eczema), when the company paid DKK 270 million (USD 39 million) and promised DKK 3.6 billion (USD 526 billion) in milestone payments for antibody FB825.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
.jpg)
